Revenue

In a landmark move, mitú appoints Vanessa Vigil as President. Her rise signals a new chapter for the media giant and a milestone for Latina leadership.

AI-first firms face a hidden 'tax,' taking 80 days longer and paying 135% more to recover from cyberattacks, a new report from Fastly reveals.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Strategic Resources navigates a key environmental review for its iron ore pellet plant, tapping into Quebec's hydro power for the global green steel market.

After a breakout first year, Maine's sustainable canned water brand is expanding into Boston and Florida, leveraging its pure origins and a veteran sales team.

Intellicheck's new desktop tool promises immediate, advanced identity verification without complex integration, leveling the security field for businesses.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

The cybersecurity firm will provide quantum-resistant tech for a massive MDA program, aiming to secure critical U.S. systems against future cyber threats.

New research shows assessment fraud more than doubled in 2025, driven by AI and hitting entry-level roles hardest. How can companies ensure fair hiring?

As AI adoption stalls at the pilot stage, new labs in Singapore, Japan, and the UK offer a crucial sandbox for testing high-stakes hybrid cloud deployments.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its fifth straight EcoVadis Platinum rating and deep data transparency, ENNOVI is building a new blueprint for accountability in the industrial sector.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.